- Home
- AXL vs PHAR Comparison
AXL vs PHAR Comparison
Compare AXL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- PHAR
- Stock Information
- Founded
- AXL 1994
- PHAR 1988
- Country
- AXL United States
- PHAR Netherlands
- Employees
- AXL N/A
- PHAR N/A
- Industry
- AXL Auto Parts:O.E.M.
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- AXL Consumer Discretionary
- PHAR Health Care
- Exchange
- AXL Nasdaq
- PHAR Nasdaq
- Market Cap
- AXL 739.6M
- PHAR 627.5M
- IPO Year
- AXL 1999
- PHAR N/A
- Fundamental
- Price
- AXL $5.99
- PHAR $8.49
- Analyst Decision
- AXL Hold
- PHAR Strong Buy
- Analyst Count
- AXL 4
- PHAR 3
- Target Price
- AXL $7.38
- PHAR $27.00
- AVG Volume (30 Days)
- AXL 1.3M
- PHAR 7.4K
- Earning Date
- AXL 02-14-2025
- PHAR 10-24-2024
- Dividend Yield
- AXL N/A
- PHAR N/A
- EPS Growth
- AXL N/A
- PHAR N/A
- EPS
- AXL 0.23
- PHAR N/A
- Revenue
- AXL $6,207,100,000.00
- PHAR $285,745,000.00
- Revenue This Year
- AXL $1.78
- PHAR $20.89
- Revenue Next Year
- AXL N/A
- PHAR $11.15
- P/E Ratio
- AXL $25.81
- PHAR N/A
- Revenue Growth
- AXL 3.29
- PHAR 30.64
- 52 Week Low
- AXL $5.43
- PHAR $6.65
- 52 Week High
- AXL $8.99
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- AXL 36.16
- PHAR 53.27
- Support Level
- AXL $6.73
- PHAR $8.71
- Resistance Level
- AXL $6.90
- PHAR $9.59
- Average True Range (ATR)
- AXL 0.23
- PHAR 0.35
- MACD
- AXL -0.09
- PHAR 0.11
- Stochastic Oscillator
- AXL 7.52
- PHAR 50.89
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.